What factors play a role when deciding whether or not to take statins?

People who have a high risk of cardiovascular disease are usually advised to take because then the advantages outweigh the disadvantages. This is particularly true of

If you've never had any of these diseases and only have a slightly increased risk of developing one, the protective effect of will be smaller. It is then particularly worth considering the pros and cons of the medication together with your doctor.

People who have a low risk often try to improve their cardiovascular health themselves at first – for example, by doing more exercise or stopping smoking. Others decide to take because the benefits – however small – are important to them. You can also change your mind later if, for example, new risk factors develop or your personal situation changes.

How is your personal risk assessed?

Your personal risk of cardiovascular disease can be determined together with your doctor using computer programs. These programs are based on data from long-term studies that monitored the health of thousands of people.

The following information is needed in order to calculate your risk:

  • Age: The risk of cardiovascular disease increases with age.
  • Biological sex: Men are at higher risk than women.
  • Family history of heart disease: The risk is higher if a brother or your father had a or stroke before the age of 55, or if a sister or your mother had a or stroke before the age of 65.
  • Smoking: The toxins in tobacco smoke can lead to and damage the blood vessel walls, among other things.
  • Blood pressure: The higher your blood pressure, the higher the risk of cardiovascular disease.
  • Type 2 diabetes: People who have type 2 diabetes are at greater risk of developing cardiovascular disease.
  • Cholesterol levels: High non-HDL are particularly unfavorable. This is a measure of the total cholesterol without HDL cholesterol. It includes all harmful lipoproteins – like LDL cholesterol, for instance.

Once calculated, your personal risk is expressed as a percentage. It reflects how likely you are to have a stroke or heart attack in the next ten years.

How does your personal risk affect the potential benefits of medication?

Statins lower the risk of cardiovascular disease by about 30%. This will mean different things for people with different initial risks. In a 50-year-old woman with no risk factors, the natural risk of a or stroke within ten years is less than 1%. In a 50-year-old man, it is 3%.

The influence of other risk factors can be shown in the following examples involving two women (Olga and Veronica) and two men (Peter and Yusuf).

They are all 50 years old and have the same . Their total cholesterol is 260 milligrams per deciliter (mg/dl), which is the same as 6.2 millimoles per liter (mmol/l). 44 mg/dl (1.1 mmol/l) of their total cholesterol is HDL cholesterol. But there are differences between the four people's other risk factors, which affect their risk of a :

  • Olga's blood pressure (145/90 mmHg) is slightly higher than the normal level but she doesn't have any other risk factors. Without treatment, her risk of a over the next ten years is 4%.
  • Veronica also has slightly high blood pressure. But she smokes and her father had a at the early age of 50. Without treatment, her risk of a over the next ten years is 18%.
  • Peter's are slightly higher than normal but he has no other risk factors. Without treatment, his risk is 11%.
  • Yusuf has very high blood pressure (162/96 mmHg). He also smokes. Without treatment, his risk of having a within the next ten years is 33%.

Statins can reduce the risk by 30% for each of these people. That means that the medication can reduce

  • Olga's risk of a from 4% to 3%,
  • Veronica's risk from 18% to 13%,
  • Peter's risk from 11% to 8% and
  • Yusuf's risk from 33% to 23%.

The ten-year risk of a with or without is shown again in the following illustrations. As we can see, wouldn't make a big difference for Olga because she doesn't have any other risk factors. Yusuf would clearly benefit more from the medication because of the higher risk for men and due to his other risk factors.

This illustration shows how the heart attack risks of two women (Olga and Veronica) differ due to their different risk factors – with and without statins.
This illustration shows how the heart attack risks of two men (Peter and Yusuf) differ due to their different risk factors – with and without statins.

What are the side effects of statins?

Statins are usually well tolerated. One possible side effect is muscle pain or muscle weakness. This is very uncommon, though. In large-scale comparative studies over a period of five years,

  • 95 out of 1,000 people who took a placebo (dummy drug) said they had muscle pain, and
  • 101 out of 1,000 people who took said they had muscle pain.

The studies also found that muscle pain is common in people who don't take . Some people who take mistakenly believe that the medication is causing this pain. So it's not a good idea to stop the treatment right away if you think it is causing a side effect. Instead, talk to your doctor first. Trying a different drug or reducing the dose might help.

Sometimes you hear that increase the risk of cataracts. But only one of several good-quality studies found this to be a side effect. Fewer than 1 out of 100 people were reported to have this side effect there. So experts think it's unlikely that lead to cataracts. There may be a small risk, though.

Statins can also lead to a slight increase in blood sugar levels, but this is very rare and doesn't usually affect the person's health.

Can statins have serious side effects?

Because the risk of serious side effects from is very low, experts agree that the advantages of taking them significantly outweigh any disadvantages.

In very rare cases, lead to muscle damage. This results in pain, weakness and swelling in the muscles – typically in the shoulders, legs or back. Muscle damage increases the amount of an enzyme called creatine kinase in the blood, so this sign of muscle damage can be detected in a blood test.

In the most severe form of muscle damage (known as rhabdomyolysis), cells of the skeletal muscles break down and enter the bloodstream in large quantities. This releases substances that can damage the kidneys. The possible signs of rhabdomyolysis include painful or rapidly tiring muscles as well as reddish or dark-colored urine. If you notice this, it's important to stop taking the and seek medical advice immediately.

In studies, muscle damage occurred in about 1 out of 10,000 people who took for more than 1 year. The severe form (rhabdomyolysis) was even rarer. It is more common if high doses are taken.

Some people are worried that the medication will build up in their body if they take it regularly over the long term. But these worries are unfounded: Our bodies continuously break down medications and get rid of them with the help of various mechanisms.

Statins might interact with certain other medications (like the antibiotic clarithromycin) so they shouldn't be taken together. Because of this, it's always important to tell your doctor what medications you are already taking. Anyone who takes should also avoid grapefruits because this fruit can prevent the drug from being broken down properly in the liver.

Are there any unanswered questions about statins?

Statins have been very well studied in research involving a lot of people. But hardly any of the participants were already over 75 years old and had no previous heart or blood vessel diseases. The risk of side effects and drug interactions can increase in older age, though.

So it's not clear whether older people without previous cardiovascular disease also benefit from starting treatment with . In order to find that out, two large studies are currently being carried out in the U.S. and Australia.

Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376(9753): 1670-1681.

Cai T, Abel L, Langford O et al. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. BMJ 2021; 374: n1537.

Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet 2019; 393(10170): 407-415.

Chou R, Cantor A, Dana T et al. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: A Systematic Review for the U.S. Preventive Services Task Force. 2022.

Cordon A, de Meester C, Gerkens S et al. Statins for the primary prevention of cardiovascular events. (KCE Report; No. 306). 2019.

Herrett E, Williamson E, Brack K et al. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. BMJ 2021; 372: n135.

Mihaylova B, Emberson J, Blackwell L et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380(9841): 581-590.

Newman CB, Preiss D, Tobert JA et al. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol 2019; 39(2): e38-e81.

Wood FA, Howard JP, Finegold JA et al. N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects. N Engl J Med 2020; 383(22): 2182-2184.

IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.

Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.

Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.

Comment on this page

What would you like to share with us?

We welcome any feedback and ideas - either via our form or by gi-kontakt@iqwig.de. We will review, but not publish, your ratings and comments. Your information will of course be treated confidentially. Fields marked with an asterisk (*) are required fields.

Please note that we do not provide individual advice on matters of health. You can read about where to find help and support in Germany in our information “How can I find self-help groups and information centers?

Über diese Seite

Updated on September 24, 2025

Next planned update: 2028

Publisher:

Institute for Quality and Efficiency in Health Care (IQWiG, Germany)

Stay informed

Subscribe to our newsletter or newsfeed. You can find our growing collection of films on YouTube.